4BIO Capital leads oversubscribed $33 Million Seed Financing of Cloverleaf Bio, Advancing Novel RNA-Based Cancer Therapeutics

• 4BIO Capital led upsized and oversubscribed round which includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting depth of industry interest in this novel RNA therapeutics platform

• Financing will support proof of concept in hepatocellular carcinoma and advancement of follow-on programs including colorectal cancer 

• Cloverleaf’s tRNA therapeutic platform, has demonstrated significantly greater potency and selectivity for cancer cells over healthy tissue in preclinical studies

  
  

London, United Kingdom, 8 September 2026 – 4BIO Capital, a specialist biotech venture firm transforming innovative technologies into breakthrough precision therapies, today announces that it has led an upsized and oversubscribed $33 million seed financing in Cloverleaf Bio (“Cloverleaf”), an RNA therapeutics company developing a novel class of engineered transfer RNA (tRNA) based payloads for cancer. The round includes meaningful participation from strategic investors AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund, alongside Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge.

The simultaneous participation of three major pharmaceutical venture arms at pre-clinical stage reflects strong industry interest in both the scientific platform and the founding team. The proceeds of the fundraise will be used to advance Cloverleaf’s two lead programs: an inhibitory tRNA asset targeting hepatocellular carcinoma through early clinical testing and an antibody-tRNA conjugate (ATC) asset targeting colorectal cancer through preclinical development.

Cloverleaf's platform is built around selective and durable inhibition of multiple RNA-modifying enzymes, a class of proteins that cancer cells become abnormally dependent on as they proliferate.

Dima Kuzmin, Co-founder and Managing Partner at 4BIO Capital said: “Cloverleaf reflects the core thesis of 4BIO: backing transformative frontier science that has the potential to become an entirely new class of cancer therapeutics with applicability to every major cancer of unmet need. The team at Cloverleaf have built a highly promising platform from a first-principles insight into a mechanism that the field has largely taken for granted for sixty years. The preclinical data on potency and selectivity is compelling, and the strategic interest from three major pharma venture arms at seed reflects how seriously the broader industry is taking this approach. We are proud to lead this round and look forward to supporting the team as they advance toward the clinic.”

Austin Draycott, PhD, CEO and Co-Founder of Cloverleaf Bio, said “We are excited to secure this financing to advance a new generation of cancer therapeutics. We're grateful to 4BIO Capital for leading this round, and to attract major strategic investors, including AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund at this stage reflects the level of scientific interest in this approach. We look forward to delivering the data that will test that conviction. We would also like to acknowledge the early support Cloverleaf received from the National Cancer Institute Small Business Innovation Research / Small Business Technology Transfer program. Federally funded research was foundational to getting this platform off the ground, and we're proud to build on that public investment as we move toward the clinic.”

Differentiated Preclinical Profile

In preclinical studies, Cloverleaf’s lead compound, CLB-001, demonstrated significantly greater potency and selectivity for cancerous cells over healthy cells. The compound retains activity in cancer cell lines resistant to both frontline chemotherapy and current-generation ADC payloads, a meaningful finding given that treatment resistance is a major clinical challenge in colorectal cancer. CLB-001 also outperformed frontline standard of care in both hepatocellular carcinoma and lung adenocarcinoma models at substantially lower doses. Tolerability studies in animals showed no increases in markers of liver damage and no signs of systemic toxicity across the dose range tested.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Project No 1R44CA295426